Argenx included on Wells Fargo’s Tactical Ideas List for Q1 2023

Wells Fargo analyst Derek Archila thinks Argenx (ARGX) shares are +20% on pos Vyvgart CIDP data in Q1 2023, and there is pos read through on Johnson & Johnson’s (JNJ) nipocalimab results in RA. He includes Argenx on Wells Fargo’s Tactical Ideas List for Q1 2023. Archila has an Overweight rating on Argenx shares with a price target of $470.